8.16 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||8.15 x 2900|
|Ask||8.16 x 800|
|Day's Range||7.63 - 8.17|
|52 Week Range||6.22 - 25.29|
|Beta (3Y Monthly)||3.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
On a per-share basis, the Henderson, Nevada-based company said it had a loss of 17 cents. Losses, adjusted for one-time gains and costs, were 27 cents per share. Spectrum Pharma shares have climbed slightly ...
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and investors' positions as of the end of the fourth quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news websites. […]
Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking i...
Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.
Spectrum Pharmaceuticals Inc. shares slid 7.6% in premarket trade Friday, after the company said it is withdrawing its Biologics License Application for Rolontis after the U.S. Food and Drug Administration asked for manufacturing-related information. The company said the decision was made because it needs more time to comply with the FDA request and that it will resubmit a BLA as soon as possible. "We are continuing to have productive discussions with the FDA and will deliver the additional information needed to support the application, " CEO Joe Turgeon said in a statement. Rolontis is a treatment for the management of chemotherapy-induced neutropenia in patients undergoing myelosuppressive chemotherapy. Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection and reduces patients' ability to fight infection. Spectrum shares have fallen 44% in the last 12 months, while the S&P 500 has gained 2.2%.
Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We've lost count of how many times insiders have accumulatedRead More...
popped Thursday after the company announced that it was selling its marketed portfolio of seven Food and Drug Administration-approved products to Acrotech Biopharma for $160 million up front, with a potential for another $140 million in regulatory and sales-based milestones. The company will reduce its staff size by about 40% as a result of the deal, with the impacted staff transitioning over to Acrotech. "This divestiture marks a major strategic shift for Spectrum to ensure laser-focus on novel, oncology drug development and commercialization," said Joe Turgeon, president and CEO of Spectrum Pharmaceuticals.
Spectrum Pharma (SPPI) completes enrollment in the first cohort of a phase II study on poziotinib for previously treated NSCLC patients with EGFR exon 20 insertion mutations. Shares rise.
Spectrum Pharma (SPPI) petitions for a BLA to the FDA regarding its lead pipeline candidate, Rolontis, to address chemotherapy-induced neutropenia in patients with breast cancer.
The biopharma announced that one of its drug candidates is closer to hitting the market, but investors aren't in a celebratory mood.
In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.
On December 21, Spectrum Pharmaceuticals’ stock price closed at $7.24, which was ~13.30% growth from the close of $6.39 on December 20. On December 20, Spectrum Pharmaceuticals’ stock price declined ~38.79% to $6.39 from the close of $10.44 on December 19. The company hit its 52-week low of $6.22 on December 20.